Humana (NYSE:HUM) Stock Price Down 2.7%

Humana Inc. (NYSE:HUM) shares traded down 2.7% during mid-day trading on Wednesday . The stock traded as low as $362.78 and last traded at $364.86. 289,561 shares changed hands during trading, a decline of 84% from the average session volume of 1,805,654 shares. The stock had previously closed at $374.82.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on HUM. Morgan Stanley assumed coverage on Humana in a report on Monday, June 24th. They issued an “equal weight” rating and a $374.00 price objective on the stock. Robert W. Baird initiated coverage on shares of Humana in a research note on Thursday, May 30th. They set a “neutral” rating and a $374.00 price objective for the company. UBS Group dropped their price objective on shares of Humana from $334.00 to $326.00 and set a “neutral” rating on the stock in a report on Thursday, April 25th. TD Cowen reduced their target price on shares of Humana from $427.00 to $396.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd. Finally, Raymond James started coverage on shares of Humana in a report on Friday, March 22nd. They issued a “market perform” rating on the stock. Fourteen investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $409.55.

Humana Stock Down 3.2 %

The company has a quick ratio of 1.67, a current ratio of 1.67 and a debt-to-equity ratio of 0.77. The company has a market capitalization of $43.72 billion, a PE ratio of 22.76, a price-to-earnings-growth ratio of 2.16 and a beta of 0.51. The firm has a 50-day moving average of $345.69 and a two-hundred day moving average of $350.79.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, topping the consensus estimate of $6.12 by $1.11. The company had revenue of $29.61 billion during the quarter, compared to analyst estimates of $28.52 billion. Humana had a net margin of 1.82% and a return on equity of 17.76%. Humana’s revenue was up 10.7% compared to the same quarter last year. During the same quarter last year, the firm posted $9.38 earnings per share. Equities research analysts predict that Humana Inc. will post 16.27 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 0.98%. The ex-dividend date is Friday, June 28th. Humana’s payout ratio is 22.04%.

Institutional Trading of Humana

A number of large investors have recently modified their holdings of HUM. Norges Bank purchased a new position in Humana in the fourth quarter worth approximately $676,800,000. Sanders Capital LLC acquired a new position in shares of Humana during the fourth quarter worth $489,300,000. Ontario Teachers Pension Plan Board increased its holdings in Humana by 11,647.2% in the first quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock valued at $367,342,000 after buying an additional 1,050,459 shares during the last quarter. Putnam Investments LLC increased its holdings in Humana by 550.3% in the fourth quarter. Putnam Investments LLC now owns 875,489 shares of the insurance provider’s stock valued at $400,808,000 after buying an additional 740,858 shares during the last quarter. Finally, Steadfast Capital Management LP purchased a new stake in Humana during the 1st quarter worth about $158,813,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.